首頁
Primrose Bio

7月 2026Primrose Bio的市場佔有率分析

Primrose Bio, Inc. enforces a final sales policy, except for damaged items or those not matching specifications. EU customers can access the Online Dispute Resolution platform.

行業: N/A

域名primrosebio.com

成立年份2023

僱員51 - 200

年度營收--

Primrose Bio

Primrose Bio（包含公司地區）

primrosebio.com

查看更多網站流量與參與度資訊

Primrose Bio的熱門網域總造訪量

了解Primrose Bio市場觸達率與潛在市場影響力。

過去 3 個月的訪問總量

子公司細目

primrosebio.com2.4K

透過銷售情報查看更多內容

Primrose Bio的熱門網域平均造訪時長

分析Primrose Bio參與度指標。

過去 3 個月平均造訪時長

子公司細目

primrosebio.com00:00:53

透過銷售情報查看更多內容

Primrose Bio的熱門網域平均頁面瀏覽量

了解Primrose Bio如何保持使用者的參與度、培養其興趣，並鼓勵他們採取下一步。

過去 3 個月平均頁面瀏覽量

子公司細目

primrosebio.com2.30

透過銷售情報查看更多內容

Primrose Bio按網域劃分的熱門競爭對手

看起來這裡的數據不足

無可顯示數據

使用的熱門技術Primrose Bio

这些是Primrose Bio顶级域名使用的行业网站技术

付款與貨幣 (8)

Cart Functionality

付費廣告 (6)

Google Adsense

小工具 (6)

reCAPTCHA

音訊視訊媒體 (3)

YouTube

更多技術

10

檢視所有

新聞與訊號來自Primrose Bio

透過 Similarweb 銷售訊號提醒，每當目標受眾出現新的機會或威脅時，你就會收到每日更新的已識別購買訊號。

新聞Intravacc partnered with Primordial Genetics Inc. on Jun 1st '26.BILTHOVEN, The Netherlands, June 01, 2026 - Intravacc, a leading global contract development and manufacturing organization (CDMO) specializing in infectious disease and therapeutic vaccines and biologics, and Primrose Bio, a biotechnology company with leading technologies that improve the manufacturing of next-generation therapeutics, renew their strategic partnership to enhance the development and supply of conjugate vaccines.

新聞Primordial Genetics Inc. launched Prima RNApols ExTend Cap AU on Nov 10th '25.Nov. 10, 2025 - Primrose Bio, Inc. ("Primrose"), a company with proprietary therapeutic manufacturing technologies, today announced the launch of Prima RNApols(TM) ExTend Cap AU, an RNA polymerase engineered to significantly improve manufacturing of self-amplifying mRNA vaccines and therapeutics.

新聞Primordial Genetics Inc. is developing novel multi-antigen vaccine for infections on Jan 10th '25.Primrose Bio, Inc. ("Primrose"), a company with proprietary manufacturing technologies for human therapeutics, and Serum Institute of India Pvt. Ltd. ("SIIPL"), the world's largest vaccine manufacturer, today announced a collaboration to develop a novel multi-antigen vaccine for infections that affect millions of people globally.